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Pediatric sarcomas are highly aggressive cancers that metastasize quickly and can return 
after treatment. Despite the use of harsh treatments, survival rates for older children and those 
with metastatic disease remain low. Oncolytic virotherapy is a promising treatment option for 
pediatric sarcomas that aims to destroy cancer cells and induce antitumor immunity using live, 
attenuated viruses such as herpes simplex-1 viruses (oHSV). Virotherapy, however, also 
stimulates the recruitment of tumor-associated immunosuppressive cells, like myeloid-derived 
suppressor cells (MDSC) and tumor-associated macrophages (TAM), to the tumor 
microenvironment. Such immunosuppressive cells limit the ability of the virus to replicate and 
spread. We hypothesize that this recruitment results in reduced therapeutic efficacy.  
Previous studies show that trabectedin, a chemotherapeutic, in combination with oHSV 
treatment enhances the efficacy of virotherapy in A673 Ewing sarcoma models. This is likely 
due to trabectedin’s ability to suppress TAM and MDSC recruitment to the tumor 
microenvironment. We termed this combination “myelolytic-virotherapy.” Though trabectedin 
was able to enhance oHSV virotherapy through the reduction of immunosuppressive cell 
recruitment, this mechanism is not well understood. Thus, there is a need to understand if solely 
targeting tumor-resident MDSC enhances virotherapy. By determining if targeting MDSC 
improves the efficacy of oncolytic virotherapy, we can develop novel myelolytic-virotherapies 
that have increased therapeutic efficacy in multiple tumor models. This could have great 
potential for pediatric cancer patients. 
Previous studies have also shown that the efficacy of oHSV virotherapy may be 
dependent on virus-induced antitumor T cell responses. Treatment with oHSV enhanced overall 
survival and induced T cell recruitment to the tumor microenvironment in M3-9-M 
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rhabdomyosarcoma models. Therefore, there is an additional need to investigate whether 
antitumor T cell responses are necessary to enhance the efficacy of oncolytic virotherapy, or if 
solely suppressing MDSC is enough.  
A study conducted by Dr. William Carson found that ibrutinib, an irreversible Bruton’s 
tyrosine kinase (BTK) inhibitor, selectively reduces MDSC recruitment to tumors and limits 
their ability to suppress T cell proliferation. Ibrutinib also improved the efficacy of immune 
based cancer therapies. We hypothesize that ibrutinib enhances oncolytic virotherapy in Ewing 
sarcoma and rhabdomyosarcoma models by inhibiting tumor-associated MDSC recruitment and 
enhancing viral replication. In this study, we performed cellular infiltrate and viral replication 
studies in A673 Ewing sarcoma models to evaluate the effect of ibrutinib on MDSC recruitment 
and oHSV replication in vivo. We also performed survival studies in A673 and M3-9-M tumor-
bearing mice to determine the effect of ibrutinib on tumor growth and survival. The results 
indicate that while ibrutinib does reduce MDSC recruitment to the microenvironment, it does not 






Pediatric sarcomas are aggressive types of childhood cancer that are often high-grade, 
fast spreading, and can recur after treatment [1]. Ewing sarcoma and rhabdomyosarcoma are two 
of the most common types of pediatric sarcomas [2]. While cure rates are relatively high for 
young patients with localized disease, the survival rate remains low for children who are older or 
experience tumor metastasis [3].  
Most pediatric sarcomas are treated using a multimodal approach that includes surgery, 
chemotherapy, and radiation [4]. These therapies, however, are harsh and often have late terms 
side effects that increase morbidity and mortality rates for childhood cancer survivors. Some of 
these side effects include growth hormone deficiency and risk of developing secondary cancers 
[5]. Therefore, there is a need for more targeted therapies that both limit long-term side effects 
and increase survival outcomes for pediatric sarcoma patients.  
 Oncolytic virotherapy is a promising potential therapy for pediatric sarcomas. Oncolytic 
virotherapy uses live, attenuated viruses, like herpes-simplex viruses, to infect and destroy tumor 
cells via lysis and activate the immune system’s antitumor responses [6]. Multiple clinical studies 
have shown that this form of therapy may require lower doses, result in less toxicity, and cause 
fewer long-term side effects in pediatric patients [7]. HSV1716, also known as Seprehvir, has 
been shown in phase I clinical trials to be safe in pediatric populations, making it a good choice 
for this study [8].  
 In addition to killing cancer cells and activating the body’s immune response, however, 
oncolytic viruses can also recruit immunosuppressive cells to the tumor microenvironment. Such 
immunosuppressive cells, like MDSC, hinder the efficacy of virotherapy by limiting the virus’ 
ability to replicate and spread. Given the potential of oncolytic virotherapy to lower the risk of 
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side effects in childhood cancer patients, there is a need to investigate if blocking the recruitment 
of these immunosuppressive cells increases therapeutic efficacy. Ibrutinib, an irreversible BTK 
inhibitor, reduces the presence of MDSC in the tumor area and may therefore improve the 
efficacy of oHSV therapy. The development of targeted treatments that combine oHSV 




Focus of the Research  
The purpose of this research is to determine if using ibrutinib to target myeloid derived 
suppressor cells via BTK inhibition enhances oncolytic virotherapy in pediatric sarcoma tumor 
models.   
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Significance of the Research  
Oncolytic virotherapy is an exciting new therapy that can be used to kill tumor cells and 
initiate an antitumor immune response in patients of all ages. In 2015, the FDA approved the first 
oncolytic virotherapy, Imlygic, after the successful completion of phase III clinical trials in 
adults with melanoma [9].  Phase I clinical trials have shown that oHSV therapy is also safe and 
well tolerated by children, which suggests it may be a good therapy choice for young populations 
[10]. Because it is safe, directly targets cancerous cells, and creates an immune response, oncolytic 
virotherapy could become an effective therapy for many different cancers and patient 
populations. Developing a better understanding of virotherapy and its impact on the tumor 
microenvironment is key to making it more effective for individuals with cancer.   
Another benefit of virotherapy is its potential to limit the long-term side effects that other 
common cancer treatments cause in pediatric patients. As the number of childhood cancer 
survivors continues to grow, the long-term effects of aggressive cancer therapies have become 
more apparent. Previous studies have shown that up to 50% of childhood cancer survivors will 
experience late effects from treatment, often decades after they are cured [11]. This makes the 
creation of targeted therapies with lower doses and fewer side-effects for children even more 
important. Pediatric sarcoma patients, who often receive high doses of both chemotherapy and 
radiation, may greatly benefit from oncolytic virotherapy.  
Research projects like this one are important because pediatric cancers are understudied, 
as is the tumor microenvironment’s influence on virotherapy. Few people, if any, are studying 
the studying the combination of myelolytic-virotherapy in pediatric tumor models. By acquiring 
a better understanding of the relationship between oncolytic viruses, the tumor 
microenvironment, and tumor-associated myeloid cells, we will be able to create novel 
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treatments for enhancing viroimmunotherapy that can be readily translated to the clinic. These 
myelolytic-virotherapies could have positive and far-reaching implications for patients of all 




Definition of Key Terms  
A673: A human Ewing sarcoma cell line.  
Athymic nude mice: Mice that lack a fully developed thymus. As a result, they are T cell 
deficient and immunodeficient.  
B6-albino mice: C57BL/6J mice that have a mutation in the tyrosinase gene. As a result, they 
lack pigment in their eyes, skin, and hair.  
Bruton’s tyrosine kinase: A tyrosine kinase that plays a key role in myeloid cell development, 
function, and signaling.  
Cd11b+: A myeloid cell marker.  
Cd11c+: A pan dendritic cell marker. 
Ewing sarcoma: An aggressive childhood cancer that most frequently occurs in the bone and soft 
tissue. It is the second most common form of pediatric bone cancer.  
gMDSC: Granulocytic myeloid-derived suppressor cell.  
HSV1716: An oncolytic herpes simplex virus-1 being used in adult and pediatric cancer clinical 
trials. It has the RL1 gene deleted, which encodes ICP34.5, a neurovirulence factor.  
Ibrutinib: An irreversible Bruton’s tyrosine kinase inhibitor that selectively reduces MDSC 
recruitment to the tumor microenvironment. It is an FDA-approved immunotherapy drug that is 
clinically used for B cell malignancies.  
M2-like TAM: Pro-tumor macrophages that suppress the host antitumor and antiviral immune 
responses.  
M3-9-M: A murine rhabdomyosarcoma cell line.  
mMDSC: Monocytic myeloid-derived suppressor cell.  
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Myeloid-derived suppressor cell (MDSC): Immature myeloid cells that suppress the immune 
system and aid in tumor evasion.   
NK: Natural killer cell.  
oHSV: Oncolytic herpes simplex virus.  
Oncolytic virotherapy: A type of cancer therapy that uses live, attenuated viruses to directly 
infect and lyse tumor cells and activate a host antitumor immune response. 
Programmed cell death protein (PD)-1: A T cell exhaustion marker that plays a role in T cell 
suppression. It is an effective therapy target for tumors that express its ligands, PD-L1 and PD-
L2.  
Rhabdomyosarcoma: A type of childhood cancer that begins in the soft tissue. It is the most 
common form of pediatric soft tissue sarcoma.   
Tumor-associated macrophage (TAM): Macrophages that have been recruited to the tumor 
microenvironment and play a role in tumor development and suppression of the immune system.  





 The efficacy of oncolytic virotherapy is dependent on both the ability of the virus to 
stimulate the host immune system’s antitumor mechanisms and the tumor microenvironment’s 
influence on immune response [12]. Previous studies have shown that virotherapy alone is only 
moderately effective in slowing tumor growth in Ewing sarcoma models, partly due to Cd11b+ 
myeloid cell infiltration [13]. MDSC are known immunosuppressors that promote tumor 
progression. By suppressing the immune response created by oncolytic virotherapy, MDSC 
hinder its therapeutic benefits [14]. To study the effects of MDSC on oncolytic virus efficacy in 
Ewing sarcoma models, A673 xenograft-bearing athymic nude mice were treated with two doses 
of trabectedin in combination with two doses of oHSV. Trabectedin is an FDA-approved 
chemotherapeutic agent that selectively depletes TAM and MDSC. The results of this study 
showed that while oHSV increased the percentage of TAM and MDSC in the cellular infiltrate, 
trabectedin reduced both cell populations. The combination of trabectedin and oHSV resulted in 
the greatest reduction of myeloid cells. In A673 Ewing sarcoma mouse models, the combination 
therapy significantly improved the survival percentage of mice compared to oHSV treatment 
alone, resulting in a 78% response rate overall [15]. While trabectedin significantly improved the 
efficacy of oHSV virotherapy, it is unclear if this effect is due to the suppression of both TAM 
and MDSC, or MDSC alone. Given these findings, it is necessary to investigate whether solely 
targeting MDSC is enough to enhance oncolytic virotherapy.  
A recent study showed that ibrutinib, an FDA-approved irreversible Bruton’s tyrosine 
kinase inhibitor, selectively reduces MDSC recruitment to the tumor microenvironment. 
Immunocompetent mice bearing EMT6 murine mammary carcinoma tumors received daily 
doses of ibrutinib or vehicle. At the conclusion of the study, the MDSC population in the tumors 
was analyzed, and ibrutinib treatment significantly reduced the CD11b+/GR-1+ population. 
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Ibrutinib treatment did not significantly reduce tumor growth, but it did improve the efficacy of 
immune based cancer therapies. A combination treatment of ibrutinib and anti-PD-L1 antibody 
resulted in a significant reduction in tumor growth in EMT6 mammary carcinoma tumor-bearing 
Balb/c mice [16]. Ibrutinib’s ability to reduce tumor-associated MDSC recruitment and enhance 
the efficacy of cancer immunotherapies suggests that the combination of ibrutinib and oHSV 
treatment would reduce tumor growth and increase the efficacy of oHSV virotherapy in Ewing 
sarcoma models.  
 In addition to suppressing the recruitment of tumor-associated MDSC, ibrutinib also 
reduced the ability of MDSC to suppress T cell proliferation [16]. Oncolytic virotherapy induces 
antitumor T cell immunity, and its efficacy may rely on an antitumor T cell response [17]. Given 
this information, ibrutinib may enhance oncolytic virotherapy by both suppressing MDSC and 
enhancing T cell proliferation.  
There are currently no immunocompetent Ewing sarcoma animal models, so in vivo 
studies must be conducted in immunocompromised mice. Because these mice lack a developed 
thymus, they cannot be used to study the relationship between ibrutinib, oHSV virotherapy, and 
antitumor T cell responses. Previous studies have shown that HSV1716 virotherapy slows tumor 
growth and enhances survival in immunocompetent, M3-9-M tumor-bearing mice [17]. The 
effects of HSV1716 virotherapy were dependent on a virus-induced antitumor T cell response. 
Given these findings, M3-9-M is an appropriate model for investigating whether the effect of 
ibrutinib on oncolytic virotherapy efficacy is dependent on enhanced T cell proliferation. 
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Research Aims and Hypotheses  
Aim 1: Determine the effect of ibrutinib on the composition of Ewing sarcoma tumor 
cellular infiltrates. An analysis of the tumor cellular infiltrate from A673 tumors treated with 
PBS control, HSV1716, ibrutinib, or a combination of ibrutinib and HSV1716 will be performed 
using flow cytometry. We expect that that A673 tumors treated with ibrutinib or the combination 
treatment will exhibit a reduced number of MDSC in comparison to the PBS control and 
HSV1716 groups. We hypothesize that ibrutinib will reduce the presence of MDSC in the Ewing 
sarcoma tumor cellular infiltrate by inhibiting Bruton’s tyrosine kinase. 
Aim 2: Determine the effectiveness of the combination of ibrutinib and HSV1716 
virotherapy in causing tumor regressions and increasing survival in Ewing sarcoma. A 
survival study in A673 xenograft-bearing nude mice will be performed using PBS control, 
HSV1716, ibrutinib, or a combination of ibrutinib and HSV1716. We expect that the 
combination therapy will result in the greatest number of tumor regressions, increase survival, 
and have the greatest therapeutic efficacy compared to ibrutinib or HSV1716 treatment alone. 
We hypothesize that the combination of ibrutinib and HSV1716 treatment will cause tumor 
regressions and increase survival in Ewing sarcoma models by reducing MDSC recruitment to 
the tumor microenvironment and activating innate antitumor mechanisms.  
Aim 3: Determine the effect of ibrutinib treatment on viral replication in HSV1716-treated 
Ewing sarcoma tumors. Serial plaque assays will be conducted using the lysates from A673 
tumors treated with HSV1716 or a combination of ibrutinib and HSV716. We expect that the 
combination therapy will result in increased viral replication compared to HSV1716 alone. We 
hypothesize that ibrutinib will enhance viral replication in HSV1716-treated Ewing sarcoma 
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tumors by reducing MDSC recruitment to the tumor microenvironment, thus allowing for 
increased viral production and spread. 
Aim 4: Determine the effectiveness of the combination of ibrutinib and HSV1716 
virotherapy in causing tumor regressions and increasing survival in rhabdomyosarcoma. A 
survival study in M3-9-M tumor-bearing B6-albino mice will be performed using PBS control, 
HSV1716, ibrutinib, or a combination of ibrutinib and HSV1716. We expect that the 
combination therapy will result in the greatest number of tumor regressions, increase survival, 
and have the greatest therapeutic efficacy compared to ibrutinib or HSV1716 treatment alone. 
We hypothesize that the combination of ibrutinib and HSV1716 treatment will cause tumor 
regressions and increase survival in rhabdomyosarcoma models by reducing MDSC recruitment 
to the tumor microenvironment and activating innate antitumor mechanisms, including antitumor 




Aim 1: Cellular infiltrate analysis. To determine the effect of ibrutinib on the composition of 
the tumor cellular infiltrate in A673 tumors, cellular infiltrate analysis using flow cytometry was 
performed. 5.0 x 106 A673 cells in a 2:1 150-uL mix of PBS and matrigel were injected 
subcutaneously into the flanks of athymic nude mice. After tumors reached a volume between 
88.6-1008.8 mm3, the mice (n=2-3) were randomized into one of four study groups: PBS control, 
HSV1716, ibrutinib, or a combination of HSV1716 + ibrutinib. Most tumor volumes were 
between 300-600 mm3. Two 1x107 pfu doses of HSV1716 were administered intratumorally to 
mice in the HSV1716 and HSV1716 + ibrutinib groups on days 0 and 2. As a control, two 100 
µL doses of PBS were administered to mice in the PBS and HSV1716 groups on days 0 and 2. 
Three days before the first HSV1716 injection, one 25 mg/kg dose of ibrutinib was administered 
via drinking water to the ibrutinib and HSV1716 + ibrutinib groups. Ibrutinib was administered 
daily for the duration of the experiment. The PBS and HSV1716 groups received vehicle 
drinking water containing 1% HP-b-cyclodextrin. Tumors were harvested 72 hours after the first 
HSV1716 injection. Single cell suspensions of tumor were created by mechanical chopping, 
followed by incubation in 25 µg/mL liverase blendzyme 3 and 250 µg/mL DNAse I for 1 hour at 
37°C. Tumor slurries were passed through a 70 µm cell strainer. 1 x 106 cells were blocked with 
5% mouse Fc (2.4G2; BD Biosciences) blocking reagent in fluorescent-activated cell sorting 
(FACS) buffer (1% FBS and 1mM EDTA in PBS). To analyze the immune cells, cells were 
stained with antibodies against CD206-fluorescein isothiocyanate (FITC) (C068C2), CD11b-
Violet 421 (M1/70), CD11c-PerCP/Cy5.5 (N418), F4/80-PE-Cy7 (BM8), Ly-6G-APC-Cy7 
(1A8), Ly6c (APC) (AL-21), and CD49b-PE (DX5) on ice for 30 minutes. The staining 
antibodies were obtained from BioLegend and BD-Biosciences (anti-Ly6C antibody). Stained 
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cells were washed in FACS buffer and fixed in 0.5% paraformaldehyde. Cellular infiltrate 
analysis was conducted using a flow cytometry machine and FlowJo software, version 10.03 
(Tree Star).   
Aim 2: Survival study in A673 Ewing sarcoma model.  To determine if the combination of 
ibrutinib and HSV1716 virotherapy causes tumor regressions and increases survival in Ewing 
sarcoma, a survival study using A673 xenograft-bearing athymic nude mice was performed. 5.0 
x 106 A673 cells in a 2:1 150-uL mix of PBS and matrigel were injected subcutaneously into the 
flanks of athymic nude mice. After tumors reached a volume between 135.4-614.3 mm3, the 
mice (n=10) were randomized into one of the four study groups: PBS control, HSV1716, 
ibrutinib, or HSV1716 + ibrutinib. Most tumors volumes were within a range of 150-250 mm3. 
Two 1x107 pfu doses of HSV1716 were administered intratumorally to mice in the HSV1716 
and HSV1716 + ibrutinib groups on days 0 and 2. As a control, two 100 µL doses of PBS were 
administered intratumorally to the PBS and HSV1716 groups on days 0 and 2. Three days prior 
to the first HSV1716 injection, one 25 mg/kg dose of ibrutinib was administered via drinking 
water to mice in the ibrutinib and HSV1716 + ibrutinib groups. Ibrutinib was administered daily 
for sixty days. Mice in the PBS and HSV1716 groups were administered vehicle drinking water 
containing 1% HP-b-cyclodextrin. Mice were weighed once per week, and tumors were 
measured twice per week. Tumor volume was calculated using the formula: a x b2 x (π/6), where 
a is the tumor length and b is the tumor width. Mice were also observed two times per week for 
signs of endpoint criteria including tumor volume >2,000 mm3, body weight loss >20%, unusual 
behavior, and lack of movement. Mice were followed until they reached endpoint criteria or until 
the conclusion of the study.  
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Aim 3: Viral replication assay. To determine the effect of ibrutinib on viral replication in 
HSV1716-treated Ewing sarcoma tumors, serial plaque assays were performed. 5.0 x 106 A673 
cells in a 2:1 150-uL mix of PBS and matrigel were injected subcutaneously into the flanks of 
athymic nude mice. After tumors reached a volume between 75.8-798.7 mm3, the mice (n=5) 
were randomized into one of two study groups: HSV1716 or HSV1716 + ibrutinib. Most tumor 
volumes were between 150-350 mm3. Three days prior to the first HSV1716 injection, one 25 
mg/kg dose of ibrutinib was administered daily via drinking water to mice in the HSV1716 + 
ibrutinib group. Ibrutinib was administered daily for the duration of the experiment. One 1x107 
dose pfu of HSV1716 was administered intratumorally to both groups on day 0. Tumors were 
harvested 3, 72, and 144 hours post HSV1716 injection. Tumors were freeze-thawed three times, 
and the lysates were collected. 1-4 log serial dilutions in plain DMEM were performed using the 
lysates. The diluted lysates were used to inoculate 12-well plates of Vero cells for 45-60 minutes 
before adding 2% carboxymethylcellulose overlay (2% carboxymethylcellulose, 1X MEM, 10% 
FBS). Vero cells were incubated at 37°C for three days. After three days, the plates were stained 
with crystal violet for 30 minutes, rinsed with tap water, and dried. To determine viral titer, viral 
plaques were counted and multiplied by serial dilution.  
Aim 4: Survival study in M3-9-M rhabdomyosarcoma model. To determine if the 
combination of ibrutinib and HSV1716 virotherapy causes tumor regressions and increases 
survival in rhabdomyosarcoma, a survival study using M3-9-M tumor-bearing B6-albino mice 
was performed. 5.0 x 106 A673 cells in 100µL of PBS were injected subcutaneously into the 
flanks of B6-albino mice. After tumors reached a volume between 131.2-674.2 mm3, the mice 
(n=5-8) were randomized into one of the four study groups: PBS control, HSV1716, ibrutinib, or 
HSV1716 + ibrutinib. Three 1x108 pfu doses of HSV1716 were administered intratumorally to 
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mice in the HSV1716 and HSV1716 + ibrutinib groups on days 0, 2, and 4. As a control, three 
100 µL doses of PBS were administered intratumorally to mice in the PBS and ibrutinib groups 
on days 0, 2, and 4. Three days prior to the first HSV1716 injection, one 25 mg/kg dose of 
ibrutinib was administered via drinking water to mice in the ibrutinib and HSV1716 + ibrutinib 
groups. Ibrutinib was administered daily for the duration of the experiment. Mice in the PBS and 
HSV1716 groups were administered vehicle drinking water containing 1% HP-b-cyclodextrin. 
Mice were weighed once per week, and tumors were measured twice per week. Tumor volume 
was calculated using the formula: a x b2 x (π/6), where a is the tumor length and b is the tumor 
width. Mice were observed two times per week for signs of endpoint criteria including tumor 
volume >2,000 mm3, body weight loss >20%, unusual behavior, and lack of movement. Mice 





Ibrutinib reduces MDSC recruitment to the A673 tumor microenvironment. Ibrutinib has 
been shown in previous studies to selectively reduce MDSC recruitment to the tumor 
microenvironment via irreversible inhibition of BTK [16]. To determine if ibrutinib reduced 
MDSC recruitment in the A673 tumor microenvironment, tumor cellular infiltrate analysis was 
performed using flow cytometry. Ibrutinib reduced the gMDSC and mMDSC populations in 
tumors treated with ibrutinib compared to those treated with PBS or oHSV alone (Fig. 1). These 
results confirmed that ibrutinib reduces MDSC recruitment in the A673 tumor 
microenvironment.  
 
Ibrutinib does not significantly reduce the recruitment of other immune cells to the A673 
tumor microenvironment. To determine if ibrutinib impacts the recruitment of other immune 
cells, we examined its effect on natural killer cells (NK), TAM, M2-like TAM, dendritic cells, 
and myeloid cells. Tumor cellular infiltrate analysis was performed using flow cytometry. 
Treatment with ibrutinib did not significantly impact the recruitment of NK, TAM, M2-like 
TAM, dendritic cells, or myeloid cells to the A673 tumor microenvironment (Fig. 2). The slight, 
nonsignificant decrease in the myeloid cell population in the ibrutinib treatment group was 
expected. Because MDSC are one type of myeloid cell, reduction of MDSC will cause a small 
decrease in the total population of myeloid cells in the tumor cell infiltrate. We also observed a 
significant difference in TAM frequency between the control group and HSV1716, ibrutinib, and 
combination groups. This result may be explained by the small sample sizes used. Small sample 
sizes may also explain the significant difference in M2-like TAM frequency between the control 
group and the HSV1716 and combination groups. This difference may also be due to treatment 
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with HSV1716, as there was no difference between tumors treated with PBS or ibrutinib alone. 
Overall, these results confirm that ibrutinib selectively targets tumor-associated MDSC in A673 
tumor-bearing mice and does not significantly affect other immune cell populations.  
 
The combination of ibrutinib and HSV1716 is safe and well-tolerated in tumor-bearing 
mice. The combination of ibrutinib and virotherapy in mice has not been tested before. To ensure 
the treatment was safe and did not cause toxicities in tumor-bearing mice, mice were weighed 
weekly starting the day that ibrutinib/vehicle was first administered. In both the A673 xenograft-
bearing athymic nude mice and the M3-9-M tumor-bearing B6-albino mice, no significant 
changes in weight were seen among any of the treatment groups (Fig. 3). This data serves as a 
safety measure and demonstrates that the combination of ibrutinib and HSV1716 is safe and 
well-tolerated in mice bearing A673 and M3-9-M tumors.  
 
Ibrutinib does not improve the efficacy of oncolytic virotherapy in A673 tumor-bearing 
mice. To assess if ibrutinib enhances the efficacy of oncolytic virotherapy in Ewing sarcoma, we 
administered 25 mg/kg of oral ibrutinib daily to A673 xenograft-bearing nude mice, along with 
two intratumoral 1x107 pfu doses of HSV1716 on days 0 and 2. In comparison to the other 
treatment groups, the combination therapy did not result in a significant increase in animal 
survival (Fig 4). We also tracked tumor growth by measuring tumors twice per week. Treatment 
with ibrutinib did not impact established A673 tumor growth in comparison to mice treated with 
HSV1716 only or PBS. (Fig 5). These results suggests that ibrutinib does not improve the 
efficacy of HSV1716 virotherapy in A673 Ewing sarcoma xenograft models, and that solely 
targeting MDSC is not enough to improve the efficacy of oncolytic virotherapy.  
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Ibrutinib does not enhance HSV1716 viral replication. To investigate the effect of ibrutinib 
on HSV1716 viral replication, we performed serial plaque assays using A673 tumor lysates. We 
treated A673 xenograft-bearing mice with daily 25 mg/kg oral doses of ibrutinib, along with one 
1x107 pfu intratumoral dose of HSV1716 on day 0. We harvested tumors at 3, 72, and 144 hours 
post viral infection. Ibrutinib did not have a significant impact on viral replication in A673 
xenografts. A673 tumors treated with the combination of ibrutinib and HSV1716 did not show a 
statistical increase in viral production compared to A673 tumors treated without ibrutinib (Fig 6). 
The significant difference we found in viral replication between virus-treated tumors at 3 hours, 
72 hours, and 144 hours post viral infection was expected. At three hours post infection, virus 
should be attaching to and infecting tumor cells, so fewer infectious units will be detected. 
Beyond three hours, we expected to detect more infectious units as the virus lyses tumor cells 
and replicates in the tumor microenvironment. Overall, the results from this viral replication 
analysis demonstrate that ibrutinib does not improve HSV1716 replication kinetics in A673 
tumors in vivo. 
 
Ibrutinib does not improve the efficacy of HSV1716 virotherapy in M3-9-M tumor-bearing 
mice. After performing the survival study detailed above in immunocompromised mice, we 
sought to determine if ibrutinib enhances the efficacy of oHSV virotherapy in 
rhabdomyosarcoma, a more immunogenic model. By using immunocompetent mice, we hoped 
to be able to assess if the presence of T cells impacted ibrutinib’s effect on virotherapuetic 
efficacy. We administered 25 mg/kg of oral ibrutinib daily to M3-9-M bearing B6-albino mice, 
along with three 1x108 pfu doses of HSV1716 on days 0, 2, and 4. The combination therapy did 
not result in a significant increase in animal survival compared to the other treatment groups (Fig 
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7). We also tracked tumor growth by measuring tumors twice per week. Treatment with ibrutinib 
did not impact established M3-9-M tumor growth in comparison to mice treated with HSV1716 
only or PBS (Fig 8). These results suggests that ibrutinib does not improve the efficacy of 
HSV1716 oncolytic virotherapy in M3-9-M rhabdomyosarcoma tumor models, and that solely 





Figure 1. Ibrutinib reduces MDSC recruitment to the A673 tumor microenvironment. Flow 





Figure 2. Ibrutinib does not significantly alter the frequency of NK, TAM, M2-like TAM, dendritic 
cells, or myeloid cells in the A673 tumor microenvironment. Flow cytometry quantification of A673 




Figure 3. (A) The combination of HSV1716 and ibrutinib is safe and well-tolerated by A673 
xenograft-bearing athymic nude mice. (B) The combination of HSV1716 and ibrutinib is safe and 
well-tolerated by M3-9-M tumor-bearing B6-albino mice. Tumor-bearing mice were weighed once a 
week beginning the first day that ibrutinib was administered. No significant weight change was 












































Figure X:  





































Figure 5. Ibrutinib does not significantly reduce tumor regressions in A673 xenograft-bearing nude 
mice when given alone or combined with HSV1716 virotherapy. A673 flank tumors treated with the 
regimen described previously were measured until tumor volume reached 2,000 mm3.  
 
Figure 4. Ibrutinib does not enhance survival in A673 xenograft-bearing athymic nude mice when 
given alone or combined with HSV1716 virotherapy. A673 flank tumors treated with the regimen 
described previously were measured until tumor volume reached 2,000 mm3.  
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Figure 6. Ibrutinib does not enhance HSV1716 virus replication in vivo. HSV1716 virus replication 
in A673 xenografts treated with one intratumoral 1x107 pfu dose of HSV1716 and with or without 
ibrutinib. Tumors were harvested 3, 144, and 72 hours post viral infection. Tumors were 




   
















Figure 7. Ibrutinib does not enhance survival in M3-9 tumor-bearing mice when given alone or 
combined with HSV1716 virotherapy. M3-9-M flank tumors treated with the regimen described 
previously were measured until tumor volume reached 2,000 mm3. 
Figure 8. Ibrutinib does not reduce tumor regressions in M3-9-M tumor-bearing mice when given 
alone or combined with HSV1716 virotherapy. M3-9-M flank tumors treated with the regimen 
described previously were measured until tumor volume reached 2,000 mm3.  
 






















This research investigated the impact of targeting myeloid-derived suppressor cells via 
BTK inhibition to enhance oHSV virotherapy in pediatric sarcoma models. The immunotherapy 
drug ibrutinib was chosen for this research because it selectively reduces MDSC recruitment to 
the tumor microenvironment. The oncolytic virus HSV1716 was selected because clinical trials 
have shown it to be safe and well-tolerated by pediatric cancer patients.  
Using cellular infiltrate analysis, we confirmed our hypothesis that ibrutinib reduces the 
presence of MDSC in the Ewing sarcoma tumor cellular infiltrate. Ibrutinib significantly reduced 
tumor-associated gMDSC populations in tumors treated with ibrutinib compared to tumors 
treated without it. It also reduced tumor-associated mMDSC populations in the ibrutinib treated 
groups, although this trend did not reach statistical significance. Our results also confirmed that 
the ibrutinib drinking water was properly formulated and that the drug was active.  
Unexpectedly, the results from the cell infiltrate analysis show that oHSV infection did 
not increase tumor-associated MDSC recruitment, as previous studies have demonstrated. There 
are multiple possible explanations for these findings. First, a prior study conducted in A673 
xenograft-bearing mice utilized the oncolytic herpes virus rRp450 instead of HSV1716 [15]. 
Different oncolytic viruses have different properties that cause unique therapeutic outcomes [19]. 
Given this information, it is possible that rRp450 infection significantly increases tumor-
associated MDSC recruitment, while HSV1716 has a less significant effect in A673 tumors. Our 
experiment also used small sample sizes. It should be repeated using larger sample sizes to gain a 
better understanding of how HSV1716 infection affects A673 tumor-associated MDSC 
recruitment.  
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We did not observe any significant impact of ibrutinib on NK, Cdllc+, TAM, M2-like 
TAM, or Cd11b+ cell populations in A673 tumors. The slight, nonsignificant reduction of 
Cd11b+ myeloid cells in ibrutinib-treated groups was expected, as MDSC are part of the myeloid 
cell population. Because ibrutinib decreased the frequency of MDSC, a slight decrease in the 
total myeloid cell population was also expected. A significant difference was observed in the 
TAM population between the control group and the HSV1716, ibrutinib, and combination 
treatment groups. This finding may be explained by the small sample sizes of the experimental 
groups (n=2-3). In the future, larger sample sizes should be used to better analyze the effect of 
various treatments on tumor cell infiltrates. Small sample size may also explain the significant 
difference in M2-like TAM frequency between the control group and the HSV1716 and 
combination treatment groups. This difference could also be due to HSV1716 treatment, as there 
was no difference between the control and ibrutinib treatment groups.  
We next sought to test our hypothesis that ibrutinib enhances HSV1716 replication in 
vivo. We found that ibrutinib does not impact viral replication in HSV1716-treated A673 tumors. 
This suggests that targeting tumor-associated MDSC does not influence HSV1716 replication 
kinetics. We did observe a significant difference in viral replication between HSV1716-treated 
tumors at 3, 72, and 144 hours post infection. These results were expected because at three hours 
post infection the virus should be attaching to and infecting tumor cells. In tumors harvested 3 
hours post infection, we calculated an average viral titer between 1x104-1x105 pfu. We 
administered a 1x107 pfu dose of virus, which means that at 3 hours post infection, 99 percent of 
the virus was infecting tumor cells. By 72 hours, the virus should have lysed open tumor cells 
and began replication, so more infectious units will be observed. This effect was sustained at 144 
hours post injection because we used tumor-bearing athymic nude mice. While these mice have 
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NK cells and macrophages that attack virus-infected cells, they lack T cells. Without T cells, the 
immune response to virus-infected cells is less effective, which leads to sustained viral 
replication at 144 hours post infection. In immunocompetent mice, we typically observe a loss of 
viral replication by one week post infection [17].  
Because the combination of HSV1716 and ibrutinib has not been tested in animal models 
before, we sought to confirm that the treatment regime was safe in vivo. To test this, we weighed 
mice once per week beginning the day that ibrutinib was first administered. No significant 
change in weight was observed in any of the treatment groups in both athymic nude mice and 
B6-albino mice, which confirms that the combination of ibrutinib and HSV1716 is safe and well-
tolerated by tumor-bearing mice.  
 To evaluate the effect of ibrutinib on oHSV virotherapy, we performed a survival study 
in A673 xenograft-bearing athymic nude mice. Treatment with ibrutinib alone or in combination 
with HSV1716 did not result in increased survival or impact tumor growth. Although we 
hypothesized that ibrutinib would enhance the efficacy of oHSV therapy by reducing tumor-
associated MDSC recruitment, our findings do not support this idea. The results suggest that 
ibrutinib does not improve the efficacy of oHSV virotherapy, and that targeting MDSC alone is 
not enough to enhance oHSV virotherapy.  
The lack of therapeutic efficacy we observed in the athymic nude mice could be due to 
the absence of T cells. Ibrutinib has been reported to reduce the suppression of T cell 
proliferation in the tumor area by targeting MDSC. Because athymic nude mice lack T cells, 
some of the efficacy of ibrutinib may be lost in these animal models. Additionally, numerous 
studies have shown that the antitumor responses initiated by oHSV therapy may be dependent on 
T cell activity. In one study, the combination of HSV1716 and A8301, a transforming growth 
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factor beta receptor 1 (TGF-βR1) inhibitor, significantly prolonged survival in M3-9-M tumor-
bearing mice. This efficacy was completely lost, however, when the therapy was tested in 
athymic nude mice [18]. Given this information, our findings support the idea that antitumor T 
cell activity is necessary to improve virotherapeutic efficacy.  
 We next tested our hypothesis that ibrutinib enhances oncolytic virotherapy in a more 
immunogenic mouse model. M3-9-M, a murine rhabdomyosarcoma cell line, was chosen 
because it responds well to HSV1716 infection and can be used in immunocompetent mice [17]. 
Ibrutinib also failed to enhance oncolytic virotherapy in M3-9-M tumor-bearing B6-albino mice. 
It did not improve survival or impact tumor growth when administered alone or in combination 
with HSV1716.  This data suggests that solely targeting tumor-resident MDSC is not enough to 
improve the therapeutic efficacy of oHSV virotherapy.  
One factor that may have influenced the results of the M3-9-M survival study was the 
rapid growth of the M3-9-M tumors. We began administering ibrutinib three days prior to viral 
infection. By the time we administered the first dose of virus, many of the tumors had volumes 
greater than 150-250 mm3. Because most tumors were larger than 150-250 mm3 when virus 
treatment began, it may have been too late to observe any therapeutic effect from the 
combination of HSV1716 and ibrutinib. When using this tumor model in future studies, we will 
monitor tumor progression more closely and consider administering ibrutinib more than three 
days prior to viral infection, so we can observe its full therapeutic effect.  
 In the future, we plan to test a triple combination therapy of ibrutinib, oHSV, and anti-
PD-1 antibody in M3-9-M tumor-bearing mice. A prior study found that ibrutinib improved the 
efficacy of anti-PD-L1 therapy in Balb/c mice bearing EMT6 mammary carcinomas. The 
combination of ibrutinib and anti-PD-L1 therapy resulted in significant tumor reduction 
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compared to either treatment alone. The combination treatment also produced more complete 
responses compared to anti-PD-L1 therapy alone [16]. Additionally, a previous Cripe lab study 
found that the combination of anti-PD-1 antibody and HSV1716 significantly prolongs survival 
in M3-9-M tumor-bearing mice [17]. Taken together, these findings suggest that the triple 
combination of ibrutinib, anti-PD-1 antibody, and HSV1716 will enhance survival via several 
different mechanisms. These mechanisms include suppressing MDSC recruitment, reducing 
MDSC suppression of T cell proliferation, preventing T cell exhaustion, and inducing T cell 
recruitment in the tumor microenvironment. We plan to perform a pilot survival study to test 
whether the combination of ibrutinib, oHSV, and anti-PD-1 antibody enhances survival in M3-9-
M tumor-bearing mice compared to the combination of oHSV and anti-PD-1 treatment. We will 
continue to use weight as a safety measure to ensure that other combination therapies are safe for 
tumor-bearing mice. We will also monitor the growth of M3-9-M tumors closely and consider 
administering ibrutinib earlier than three days before oHSV infection.  
The present research found that while ibrutinib does reduce tumor-associated MDSC 
recruitment, it does not enhance oHSV virotherapy in A673 and M3-9-M pediatric sarcoma 
models in vivo. Additionally, it does not improve HSV1716 replication in A673 tumors in vivo. 
The current findings suggest that solely targeting tumor-resident MDSC is not sufficient to 
improve the efficacy of oHSV virotherapy. More research must be conducted to fully understand 
the relationship between the tumor microenvironment and oncolytic virotherapy. The influence 
of the tumor microenvironment on the efficacy of oncolytic virotherapy will continued to be 
investigated in future studies with the ultimate goal of creating targeted myelolytic-virotherapy 
treatments that limit long term- side effects and improve outcomes for pediatric sarcoma patients.    
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